Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

This study has been completed.
Hoffmann-La Roche
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: August 9, 2010
Last updated: October 3, 2016
Last verified: October 2016
This is a randomized, Phase II, double-blind, multicenter, placebo controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of MetMAb + bevacizumab + paclitaxel and MetMAb + placebo + paclitaxel versus placebo + bevacizumab + paclitaxel in patients with metastatic or locally recurrent, triple-negative breast cancer who either have not received treatment (first line) or have progressed after one conventional cytotoxic chemotherapy regimen (second-line).

Condition Intervention Phase
Breast Cancer
Drug: MetMAb
Drug: bevacizumab
Drug: paclitaxel
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Phase II, Multicenter, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Progression-free survival (PFS) or death on study from any cause [ Time Frame: Time from randomization to disease progression or relapse or death from any cause within 30 days of the last study treatment, whichever occurs first. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Objective response [ Time Frame: Complete or partial response maintained >/= 4 weeks. ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: Initial complete or partial response to disease progression or death on study from any cause, whichever occurs first. ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Randomization to death from any cause. ] [ Designated as safety issue: No ]

Enrollment: 185
Study Start Date: March 2011
Study Completion Date: March 2016
Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Onartuzumab + Bevacizumab + Paclitaxel Drug: MetMAb
Intravenous repeating dose
Drug: bevacizumab
Intravenous repeating dose
Drug: paclitaxel
Intravenous repeating dose
Experimental: Onartuzumab + Placebo + Paclitaxel Drug: MetMAb
Intravenous repeating dose
Drug: paclitaxel
Intravenous repeating dose
Drug: placebo
Intravenous repeating dose
Active Comparator: Placebo + Bevacizumab + Paclitaxel Drug: bevacizumab
Intravenous repeating dose
Drug: paclitaxel
Intravenous repeating dose
Drug: placebo
Intravenous repeating dose


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women age >/= 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically confirmed ER-, PR-, and HER2-negative (triple-negative) adenocarcinoma of the breast
  • Confirmed availability of tumor tissue

Exclusion Criteria:

  • Prior therapy with two or more regimens for metastatic breast cancer
  • Any systemic anti-cancer therapy within 3 weeks prior to Day 1 of Cycle 1
  • Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1 of Cycle 1
  • Prior therapy with a taxane for metastatic breast cancer
  • Prior therapy with bevacizumab, sorafenib, sunitinib, or other putative VEGF pathway-targeted therapy following diagnosis of breast cancer
  • Prior therapy with hormones and/or trastuzumab
  • Inadequate hematology, renal, or hepatic organ function

Bevacizumab exclusion criteria

  • Uncontrolled hypertension (systolic pressure > 150 mmHg and/or diastolic pressure > 100 mmHg), with or without anti-hypertensive medication
  • Evidence of bleeding diathesis or coagulopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01186991

  Hide Study Locations
United States, Arizona
Phoenix, Arizona, United States, 85259
United States, California
Bakersfield, California, United States, 93309
Fullerton, California, United States, 92835
Los Angeles, California, United States, 90095-1772
Los Angeles, California, United States, 90095
Sacramento, California, United States, 95825
San Diego, California, United States, 92123
San Francisco, California, United States, 94115
San Luis Obispo, California, United States, 93454
Santa Ana, California, United States, 92705
Vallejo, California, United States, 94589
United States, Florida
Fort Lauderdale, Florida, United States, 33308
Fort Myers, Florida, United States, 33916
Hollywood, Florida, United States, 33021
Jacksonville, Florida, United States, 32207
Jacksonville, Florida, United States, 32224
United States, Georgia
Lawrenceville, Georgia, United States, 30045
United States, Kansas
Wichita, Kansas, United States, 67214-3728
United States, Massachusetts
Boston, Massachusetts, United States, 02114
United States, Michigan
Detroit, Michigan, United States, 48201
United States, Nevada
Las Vegas, Nevada, United States, 89148
United States, New York
East Setauket, New York, United States, 11733
United States, North Carolina
Durham, North Carolina, United States, 27710
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Charleston, South Carolina, United States, 29414
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga, Tennessee, United States, 37404
Nashville, Tennessee, United States, 37203
United States, Texas
Houston, Texas, United States, 77030
United States, Utah
Ogden, Utah, United States, 84403
Bruxelles, Belgium, 1000
Edegem, Belgium, 2650
Gent, Belgium, 9000
Haine-Saint-Paul, Belgium, 7100
Hasselt, Belgium, 3500
Liège, Belgium, 4000
Wilrijk, Belgium, 2610
Bordeaux, France, 33076
Caen, France, 14076
Dijon, France, 21079
Lyon, France, 69008
Montpellier, France, 34298
Paris, France, 75231
Saint Herblain, France, 44805
St Cloud, France, 92210
Toulouse, France, 31052
Toulouse, France, 31059
Aschaffenburg, Germany, 63739
Essen, Germany, 45122
Frankfurt am Main, Germany, 60590
Muenchen, Germany, 81675
München, Germany, 80637
Oldenburg, Germany, 26133
Tübingen, Germany, 72076
Cádiz, Cadiz, Spain, 11009
Majadahonda, Madrid, Spain, 28222
Barcelona, Spain, 08035
Barcelona, Spain, 08907
Jaen, Spain, 23007
La Coruña, Spain, 15009
United Kingdom
Brighton, United Kingdom, BN2 5BD
Chelsmford, United Kingdom, CM1 7ET
London, United Kingdom, SE1 9RT
Manchester, United Kingdom, M20 4BX
Northwood, United Kingdom, HA6 2RN
Nottingham, United Kingdom, NG5 1PB
Wirral, United Kingdom, CH63 4JY
Sponsors and Collaborators
Genentech, Inc.
Hoffmann-La Roche
Study Director: See-Chun Phan, M.D. Genentech, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Genentech, Inc. Identifier: NCT01186991     History of Changes
Other Study ID Numbers: OAM4861g  GO01334 
Study First Received: August 9, 2010
Last Updated: October 3, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Immunologic Factors processed this record on January 18, 2017